Novartis’ Afinitor wins landmark US approval
May 6, 2011Sales and Marketing Afinitor, Novartis
Novartis’ Afinitor has been approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in …
Digital Pharma: Sanofi Pasteur MSD takes Quora approach to vaccines
May 6, 2011Medical Communications Digital Pharma blog, Sanofi Pasteur, vaccines
Sanofi Pasteur MSD is aiming to tackle myths and misconceptions about vaccines with a Quora-like online health information campaign in …
Jon Clark gains European leadership role at Nitrogen
May 6, 2011Medical Communications appointment, medical communications
Huntsworth Health has promoted Jon Clark to European managing director of its brand communications agency Nitrogen. He will report to …
Ogilvy picks Carsten Edwards to lead new market access business
May 6, 2011Medical Communications, Sales and Marketing Ogilvy, Ogilvy Healthworld Market Access, medical communications
Ogilvy Healthworld has appointed Carsten Edwards to head its new market access business. Edwards will be managing partner of market …
Thomas Lingelbach appointed chief executive of Intercell
May 5, 2011Research and Development appointment, research and development
Vienna-based biotech Intercell has appointed Thomas Lingelbach as chief executive with effect from 10 May. He has more than twenty …
INC Research to acquire Kendle
May 5, 2011Research and Development INC Research, Kendle, cros
Two contract research organisations INC Research and Kendle International are to merge to create a new major player in the …
Sanofi signs malaria research alliance
May 5, 2011Research and Development Medicines for Malaria Venture, Sanofi-Aventis, malaria
Sanofi-Aventis has signed a research deal with the Medicines for Malaria Venture charity. They will work together to identify, characterise …
Prostate cancer drug Zytiga gains US approval
May 5, 2011Sales and Marketing Centocor Ortho Biotech, Johnson & Johnson, Zytiga, prostate cancer
Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …
Plavix sales plummet in England
May 5, 2011Sales and Marketing BMS, Plavix, Sanofi-Aventis, clopidogrel
GP prescriptions for Plavix saw a significant drop in England last year as doctors opted for cheaper generic forms of …
Debiopharm and Yale University to develop autoimmune treatment
May 5, 2011Research and Development Debiopharm, Yale University
Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …
Pfizer sales flat as Lipitor revenues decline
May 4, 2011Sales and Marketing Pfizer
Pfizer’s sales decreased slightly in the first quarter after rising revenues in specialty care and emerging markets failed to offset …
Hospitals face greater than expected savings target
May 4, 2011Monitor, NHS reforms, foundation trusts
Hospitals are being asked to nearly double their savings target as a result of the increasingly tough economic environment they …
Avastin as effective as Lucentis in eye disease
May 4, 2011Research and Development Lucentis, avastin, off label, wet AMD
Roche’s cancer drug Avastin is as effective at treating wet AMD as Novartis’ Lucentis, which is licensed for the eye …
Astellas adds senior executives to global development team
May 4, 2011Research and Development appointment, research and development
Astellas Pharma has made four new senior appointments to its US-based global development team. Former Eli Lilly vice president of …
Service Insight: Due diligence in emerging markets for clinical development
May 4, 2011Research and Development Service Insight, Talking Point, research and development
SERVICE INSIGHT Currently, the pharma industry is experiencing an unprecedented wave of blockbuster drug patent expiries. There is a lack …
Contract research news in brief
May 4, 2011Research and Development contract research, cros, research and development
This week’s CRO news roundup includes Omnicare CR and LAB Research changing hands, Q1 financials for ICON and PPD and …
UK pharma reassured over dealings with health bodies
May 3, 2011Medical Communications, Sales and Marketing 2011 ABPI Code, Code of Practice, medical communications, risk-sharing
UK pharma has been reassured over the use of risk-sharing schemes with health bodies. The latest revisions to the ABPI …
US approval for Boehringer’s diabetes drug Tradjenta
May 3, 2011Sales and Marketing Boehringer Ingelheim, Tradjenta, diabetes, lilly
Tradjenta, the once-daily oral type II diabetes treatment developed by Boehringer Ingelheim, has been approved by US regulators. The FDA …
Strides Arcolab facility gets the nod from FDA
May 3, 2011Manufacturing and Production Pfizer, distribution issues
Indian pharmaceutical manufacturer Strides Arcolab has been given a green light from the FDA for a facility in Bangalore that’s …
Cephalon accepts Teva’s $6.8 billion white knight bid
May 3, 2011Research and Development, Sales and Marketing Cephalon, Teva, Valeant, generics
Generics giant Teva has acquired Cephalon for $6.8 billion and says the deal will make it a leading specialty pharmaceutical …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
